Triad of acute infusion-related reactions associated with liposomal amphotericin B: Analysis of clinical and epidemiological characteristics

Clinical Infectious Diseases

Volumn 36, Issue 10, 2003, Pages 1213-1220

  Roden, Maureen M ^a   Nelson, Lucienne D ^a   Knudsen, Tena A ^a   Jarosinski, Paul F ^b   Starling, Judith M ^b   Shiflett, Stacey E ^b   Calis, Karim ^b   DeChristoforo, Robert ^b   Donowitz, Gerald R ^c   Buell, Donald ^d   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Fujisawa Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DIPHENHYDRAMINE;

ABDOMINAL PAIN; ACUTE INFUSION RELATED REACTION; ADULT; ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLANK PAIN; FLUSHING; HUMAN; HYPOXIA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXYGEN THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; STATISTICAL ANALYSIS; THORAX PAIN; URTICARIA;

ABDOMINAL PAIN; ADULT; AMPHOTERICIN B; ANOXIA; ANTIBIOTICS, ANTIFUNGAL; CHEST PAIN; DRUG COMBINATIONS; DYSPNEA; FEMALE; FLUSHING; HUMANS; LIPOSOMES; MALE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RISK FACTORS;

EID: 0038183841     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374553     Document Type: Article

References (19)

1. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-29.
2. Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 1998; 18:1053-61.
3. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343-500.
4. Utz JP, Bennett JE, Brandiss WT, et al. Amphotericin B toxicity. Ann Intern Med 1964; 61:334-54.
5. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6:154-64.
6. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20:755-61.
7. Walsh TJ, Finberg R, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-71.
8. Arning M, Heer-Sonderhoff AH, Wehmeier A, et al. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995; 14:41-3.
9. Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991; 114:664-6.
10. Cesaro S, Calore E, Messina C, Zanesco L. Allergic reaction to the liposomal component of liposomal amphotericin B. Support Care Cancer 1999; 7:284-6.
11. Ringden O, Andstrom E, Remberger M, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994; 14(Suppl 5):S10-4.
12. Bishara J, Weinberger M, Lin AY, et al. Amphotericin B - not so terrible. Ann Pharmacother 2001; 35:308-10.
13. Walsh TJ, Pappas P, Winston BJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
14. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L-Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155-63.
15. Ellis ME, al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992; 36:172-9.
16. Oldfield EC III, Garst PD, Hostettler C, et al. Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother 1990; 34:1402-6.
17. Gabizon A, Isacson R, Libson E, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994; 33:779-86.
18. Olson F, Mayhew E, Maslow D, et al. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982; 18:167-76.
19. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999; 99:2302.